ScreenerHero

INMInMed Pharmaceuticals Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · inmedpharma.com
1.460USDMkt Cap: 7.80M $P/E: —

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap7.80M $
Enterprise Value522.09K $
Revenue (TTM)4.94M $
Gross Profit1.71M $
Net Income (TTM)-8.16M $
Revenue/Share1.470 USD
Last Price1.460 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees13
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA4576376012
Valuation
P/E (Trailing)—
P/E (Forward)-0.25
PEG—
EV/EBITDA-0.07
EV/Revenue0.11
P/S1.71
P/B0.76
EPS (TTM)-1.46
EPS (Forward)-6.25
52W Range
1.4506% of range1.615
52W High1.615 USD
52W Low1.450 USD
Profitability
Gross Margin34.53%
Oper. Margin-162.75%
EBITDA Margin-158.51%
Profit Margin-165.14%
ROE-60.76%
ROA-52.39%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.77M $
CapEx (TTM)—
FCF Margin-79.63%
FCF Yield-50.49%
Net Debt-4.78M $
Net Debt/EBITDA0.61
Balance Sheet
Debt/Equity0.06
Current Ratio3.12
Quick Ratio2.35
Book Value/Sh2.080 USD
Cash/Share1.569 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 6, 2020
Splits
Last Split1:20
Split DateNov 14, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.5.34M
Float585.79K
Insiders0.12%
Institutions84.66%
Short Interest
Short Ratio0.0d
Short % Float1.56%
Short % Out.1.56%
Shares Short83.06K
Short (prev mo.)141.78K
Technical
SMA 501.544 (-5.5%)
SMA 2001.198 (+21.9%)
Beta0.98
S&P 52W Chg21.00%
Avg Vol (30d)71.53K
Avg Vol (10d)81.59K
Technical Indicators
RSI (14)46.5
MACD-0.0134
MACD Signal-0.0197
MACD Hist.+0.0063
BB Upper1.666 USD
BB Middle1.497 USD
BB Lower1.328 USD
BB Width22.61%
ATR (14)0.1256 USD
Vol Ratio (20d)0.54x